Lunasin: A promising polypeptide for the prevention and treatment of cancer

Xing Wan1, Hong Liu1, Yong Sun2

  • 1School of Medicine, Hubei University for Nationalities, Enshi, Hubei 445000, P.R. China.

Oncology Letters
|June 11, 2017
PubMed

Insights

Soybean-derived lunasin shows significant anti-cancer activity. This review examines lunasin

Area of Science:

  • Molecular oncology and cancer prevention.
  • Nutritional science and chemoprevention.

Background:

  • Current cancer treatment strategies are limited by incomplete understanding of carcinogenesis.
  • Diet and lifestyle significantly influence cancer development and progression.
  • Soybean-derived proteins and polypeptides show promise in cancer inhibition.

Purpose of the Study:

  • To review the molecular mechanisms of lunasin's anti-cancer effects.
  • To examine the potential benefits of lunasin in cancer prevention and treatment.
  • To provide a reference for developing natural product-based cancer therapies.

Main Methods:

  • Comprehensive literature review of studies on lunasin.
  • Analysis of molecular mechanisms underlying lunasin's anti-cancer activity.
  • Evaluation of lunasin's efficacy in cancer prevention and treatment models.

Main Results:

  • Lunasin, a 43-amino acid soybean polypeptide, exhibits notable anti-cancer properties.
  • Studies indicate lunasin can inhibit cancer progression at various stages.
  • Evidence supports lunasin's role in modulating carcinogenesis pathways.

Conclusions:

  • Lunasin is a promising natural compound for cancer prevention and treatment.
  • Further research into lunasin's molecular targets can guide development of novel therapies.
  • Dietary and lifestyle interventions involving soybean-derived compounds like lunasin warrant consideration.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.0K
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
8.3K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K